Coagulation factor ix Disease Interactions
There are 2 disease interactions with coagulation factor ix.
Prothrombin complex (applies to coagulation factor ix) heparin-induced thrombocytopenia
Major Potential Hazard, Moderate plausibility.
The brand name products, Kcentra and Bebulin of prothrombin complex, contain heparin; therefore, their use is contraindicated in patients with known heparin-induced thrombocytopenia.
References (1)
- (2013) "Product Information. Kcentra (prothrombin complex)." CSL Behring LLC
Prothrombin complex (applies to coagulation factor ix) thromboembolism
Major Potential Hazard, Moderate plausibility. Applicable conditions: Coagulation Defect, Thrombotic/Thromboembolic Disorder, Thrombotic Thrombocytopenic Purpura, Myocardial Infarction, Pulmonary Embolism, Disseminated Intravascular Coagulation
The brand name product, Kcentra of prothrombin complex is contraindicated in patients with disseminated intravascular coagulation (DIC). Both fatal and non-fatal arterial thromboembolic events (including acute myocardial infarction and arterial thrombosis), and venous thromboembolic events (including pulmonary embolism and venous thrombosis) and disseminated intravascular coagulation have been reported with the use of this product in clinical trials and post marketing surveillance. Exercise care if using this product in patients with a history of thromboembolic events.
References (1)
- (2013) "Product Information. Kcentra (prothrombin complex)." CSL Behring LLC
Switch to consumer interaction data
Coagulation factor ix drug interactions
There are 8 drug interactions with coagulation factor ix.
More about coagulation factor ix
- coagulation factor ix consumer information
- Check interactions
- Compare alternatives
- Reviews (5)
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous coagulation modifiers
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.